New malaria shots could replace daily pills
NCT ID NCT07011511
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This early-stage trial tests whether two new long-acting injectable drugs, MMV055 and MMV371, are safe and how they work in the body. Up to 72 healthy adults will receive one or two shots and be monitored for up to 48 weeks. The goal is to find a dose that could one day prevent malaria with just a few injections.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
MMV055 and MMV371 (long-acting injectable drugs)
What this could lead to
If successful, this could lead to a long-acting injection that prevents malaria for weeks or months, reducing the need for daily pills.
What could go wrong
This is a very early (Phase 1) safety study in only 72 healthy people. The drugs may not work as hoped or could cause side effects like injection site reactions.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MALARIA FALCIPARUM are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Quotient Sciences
RECRUITINGNottingham, NG11 6JS, United Kingdom
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••